Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Gain Therapeutics (GANX)

Gain Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GANX
DateTimeSourceHeadlineSymbolCompany
30/05/202412:00GlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024NASDAQ:GANXGain Therapeutics Inc
14/05/202421:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GANXGain Therapeutics Inc
14/05/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
14/05/202412:30GlobeNewswire Inc.Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
24/04/202414:25GlobeNewswire Inc.Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
08/04/202414:25GlobeNewswire Inc.Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerNASDAQ:GANXGain Therapeutics Inc
01/04/202414:25GlobeNewswire Inc.Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerNASDAQ:GANXGain Therapeutics Inc
26/03/202412:00GlobeNewswire Inc.Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
15/03/202418:30GlobeNewswire Inc.Gain Therapeutics to Present at Public Ventures Discovery DayNASDAQ:GANXGain Therapeutics Inc
05/03/202413:00GlobeNewswire Inc.Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
27/02/202419:00GlobeNewswire Inc.Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
22/02/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
14/02/202417:29GlobeNewswire Inc.Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightNASDAQ:GANXGain Therapeutics Inc
06/02/202414:56GlobeNewswire Inc.UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
06/02/202413:00GlobeNewswire Inc.Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
31/01/202422:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
31/01/202413:00GlobeNewswire Inc.Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational UpdateNASDAQ:GANXGain Therapeutics Inc
02/01/202421:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GANXGain Therapeutics Inc
02/01/202413:00GlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024NASDAQ:GANXGain Therapeutics Inc
02/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GANXGain Therapeutics Inc
19/12/202321:52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:GANXGain Therapeutics Inc
01/12/202313:00GlobeNewswire Inc.Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis ModelNASDAQ:GANXGain Therapeutics Inc
29/11/202313:00GlobeNewswire Inc.Gain Therapeutics to Participate in AI Driven Drug Discovery SummitNASDAQ:GANXGain Therapeutics Inc
24/11/202318:01GlobeNewswire Inc.Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment OptionNASDAQ:GANXGain Therapeutics Inc
24/11/202311:07Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
22/11/202322:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
21/11/202313:54GlobeNewswire Inc.Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and WarrantsNASDAQ:GANXGain Therapeutics Inc
20/11/202321:22Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
20/11/202321:03GlobeNewswire Inc.Gain Therapeutics Announces Proposed Public OfferingNASDAQ:GANXGain Therapeutics Inc
17/11/202321:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GANX

Your Recent History

Delayed Upgrade Clock